China
Africa
Explore chapters and articles related to this topic
Vulvar Disorders
Published in S Paige Hertweck, Maggie L Dwiggins, Clinical Protocols in Pediatric and Adolescent Gynecology, 2022
Tina Ho, Kaiane Habeshian, Kelsey Flood, Sameen Nooruddin, Laura Hollenbach, Kathryn Stambough, Kalyani Marathe
For vulvovaginal involvement therapies includeTopical glucocorticoids applied to the external genitalia to prevent labial agglutination and/or intravaginal application to prevent vaginal stenosisPlacement of vaginal molds to prevent adhesion formation in patients that are tampon users or sexually activeMenstrual suppression to prevent the development of vaginal adenosis during the active phase of the diseaseOnce disease process clears, consider continued speculum evaluation of vagina to assess for adenosis with biopsy of any lesion
The twentieth century
Published in Michael J. O’Dowd, The History of Medications for Women, 2020
According to Lanier and associates (1973), it appeared that about 4 per 1000 women exposed to the drug in utero were likely to develop cancer. Abnormalities of the vagina and cervix were frequently found to be diagnostic of in utero DES exposure, vaginal adenosis being the most common abnormal finding. A cervical hood or ‘cockscomb’ appearance was described along with other abnormalities of the cervix and vagina, all of which varied in their frequency and severity. Abnormalities of the uterine cavity (in particular a T-shaped irregularity of the cavity) or of the Fallopian tubes were reported in up to two thirds of DES exposed women. There was general agreement that the frequency of late pregnancy complications, preterm delivery and perinatal death were increased in women who clearly exhibited changes due to in utero exposure to DES (O’Dowd and Philipp, 1994).
Histogenesis of Irreversible Changes in the Female Genital Tract After Perinatal Exposure to Hormones and Related Substances
Published in Takao Mori, Hiroshi Nagasawa, Toxicity of Hormones in Perinatal Life, 2020
In women exposed to DES in fetal life after the 18th week of gestation, anomalies are rarely seen in the uterine cervix and vagina.112-114 Clinically manifest vaginal adenosis has been reported with an incidence of 35 to 90% in different series after early exposure.115 The incidence is higher and the adenosis more widespread in DES women than in unexposed women.115 Vaginal adenosis is a dynamic condition which is progressively replaced with squamous epithelium through metaplasia.116,117 The incidence and extension of DES-induced adenosis is closely associated with both the timing of fetal exposure to DES and age at clinical examination.116
Spontaneous de novo vaginal adenosis resembling Bartholin’s cyst: A case report
Published in Alexandria Journal of Medicine, 2018
Adebayo Alade Adewole, Osadolor Augustine Ugiagbe, Temitope Gabriel Onile, Olatunji Oluwaseyi Fadahunsi, Daniel Ike Awelimobor, Toba Ajagun, Obioma Jude Nnorom
Vaginal adenosis is defined by the presence of metaplastic cervical or endometrial epithelium within the vaginal wall, considered as derived from Mullerian epithelium islets in later life.1 It is a benign vaginal lesion attributed to intrauterine and neonatal exposure to diethylstilbesterol (DES), other progestogens and non-steroidal estrogens.1,2 They also occur in otherwise healthy women and in some cases have been considered to be idiopathic or congenital.1–3 They are sometimes considered as precancerous lesions as clear cell adenocarcinoma patients have these lesions in close proximity to atypical tuboendometrial glands.2–4 Post pubertal lesions have also been observed to grow de novo.5